CSF2 and Sepsis: In 2002, a randomized, double-blind, placebo-controlled phase II study showed that intravenous injection of low-dose GM-CSF (3 μg kg−1·d−1) improved the oxygenation index in sepsis patients with respiratory insufficiency, but it did not improve the 30-days survival rate (Presneill et al., 2002).